Table 1:
Demographic and key phenotypic characteristics 390 patients with known Sjögren syndrome, stratified by anti-Ro60 and anti-52 antibody profiles (categorical variables)
| Feature | Antibody profiles | P value | ||||||
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| Group A: Anti-Ro60+anti-Ro52 n=227, (%) | Group B: Anti-Ro60 alone n=65, (%) | Group C: Anti-Ro52 alone n=58, (%) | Group D: Anti-Ro negative n=40, (%) | Overall A-C | A vs B | A vs C | B vs C | |
| Women | 208 (92) | 60 (92) | 53 (91) | 36 (90) | 0.98 | |||
| Caucasian | 187 (82) | 55 (85) | 45 (78) | 37 (93) | 0.58 | |||
| Dry eye symptoms | 208 (92) | 55 (85) | 54 (93) | 39 (98) | 0.18 | |||
| Dry mouth symptoms | 202 (89) | 57 (88) | 52 (90) | 35 (88) | 0.94 | |||
| Salivary gland enlargement | 67 (30) | 6 (9) | 14 (24) | 12 (30) | 0.004 | |||
| Schirmer ≤ 5 mm/5 min in at least one eye | 160/213 (75) | 42/61 (69) | 43/55 (78) | 31/40 (78) | 0.48 | |||
| Abnormal ocular surface staining* | 97/150 (65) | 14/39 (36) | 18/40 (45) | 16/28 (57) | 0.0015 | 0.0011 | 0.0004 | 0.2181 |
| UWSF ≤ 0.5 mL/5 min | 49/86 (57) | 14/25 (56) | 12/16 (75) | 11/18 (61) | 0.38 | |||
| FLS with FS ≥ 1 | 98/129 (76) | 17/53 (32) | 25/42 (60) | 40/40 (100) | <0.0001 | <0.0001 | <0.0001 | 0.0151 |
| Hypoechoic foci on parotid gland ultrasonography | 42/62 (68) | 4/8 (50) | 4/13 (31) | 1/11 (9) | 0.04 | |||
| Abnormal salivary gland scintigraphy | 14/68 (21) | 17/31 (55) | 8/19 (42) | 9/15 (60) | 0.002 | |||
| ANA ≥ 1:320 | 182/226 (81) | 17/65 (26) | 25/58 (43) | 9/39 (23) | <0.0001 | <0.0001 | <0.0001 | 0.0223 |
| SSB/La antibodies | 132 (58) | 8 (12) | 10 (17) | 0 | <0.0001 | <0.0001 | <0.0001 | 0.5529 |
| Rheumatoid factor | 130/227 (57) | 6/63 (10) | 20/58 (34) | 1/40 (3) | <0.0001 | <0.0001 | <0.0001 | 0.0008 |
| IgG ≥ 15.6 g/L | 103/221 (47) | 10/63 (16) | 10/56 (18) | 0/39 (0) | <0.0001 | <0.0001 | <0.0001 | 0.8402 |
| C4 < 0.12 g/L | 23/219 (11) | 1/62 (2) | 3/56 (5) | ¾0 (8) | 0.05 | |||
| WBC ≤ 4.0×109/L | 51/224 (23) | 8/64 (13) | 10/57 (18) | 6/40 (20) | 0.17 | |||
| Monoclonal gammopathy | 31/217 (14) | 4/59 (7) | 7/53 (13) | 7/35 (20) | 0.31 | |||
| Associated systemic rheumatic disease | 40/227 (18) | 9 (14) | 10 (17) | 7 (18) | 0.77 | |||
| Systemic involvement† | 201 (89) | 62 (95) | 50 (86) | 33 (83) | 0.20 | |||
| Lymphoma†† | 12 (5) | 1 (2) | 3 (5) | 0 (0) | 0.43 | |||
Abbreviations: ANA, antinuclear antibody; C4, complement 4 protein; FLS, focal lymphocytic sialadenitis; FS, focus score; IgG, Immunoglobulin G; OSS: ocular staining score; RF, rheumatoid factor; USWF, unstimulated whole saliva flow rate; WBC, white blood cells
Abnormal ocular surface staining included any abnormal ocular staining score (OSS) and/or van Bijsterveld score in a patient.
Fulfillment of one or more non-glandular domains of the ESSDAI[13]
Marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) in 14 patients; the diagnosis of SS preceded that of lymphoma in 12 and was concomitant with that of lymphoma in the remaining four.